Keeping up with the rapid pace of technological advances in the life sciences can be daunting, but Booz Allen has your back. We've collected insights from our own health and data science leaders to predict what federal health agencies should look out for in 2021.
Download this report to learn more about the latest in these three areas:
- Biosimilar Development
Biological products are the fastest-growing class of therapeutic products in the U.S. They now account for a large proportion of the nation's healthcare costs. FDA review of such products is rigorous and often lengthy, but biosimilar development carries the potential to increase patient safety, improve treatments, and reduce the cost of lifesaving drugs.
- Biosecurity Countermeasures
The standup of Operation Warp Speed in response to the COVID-19 pandemic has accelerated timelines to develop, manufacture, and distribute safe vaccines. But how can we make sure that we're effectively mitigating biosecurity threats?
- Scientific Computing
As the amount of available healthcare data continues to grow, effective analysis requires more and more computing power. Scientific computing has the capability to help successfully integrate data and analysis resources to efficiently inform decision-making. Is your agency ready?